0000358654
Donate

Reimbursement status:
No reimbursement

Cancer: Multiple myeloma and plasma cell neoplasms

Indication:

Thalidomide in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy.

Reimbursement information:

EPAR/SmPC

Details

ATC category :
L04AX
L04AX Other immunosuppressants
EMA approval status :
Approved
EMA approval date :
2008-04-16
EMA conditional? :
No
EMA orphan? :
No
EMA biological? :
No